Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
9.97
+0.16 (1.63%)
Oct 8, 2026, 4:00 PM EDT - Market closed
Puma Biotechnology Employees
Puma Biotechnology had 179 employees as of December 31, 2025. The number of employees increased by 7 or 4.07% compared to the previous year. That makes Puma Biotechnology the 27,599th largest employer in the world and 3,494th in the United States.
Employees
179
Change (1Y)
7
Growth (1Y)
4.07%
Revenue / Employee
$1,291,866
Profits / Employee
$149,263
Market Cap
514.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 179 | 7 | 4.07% |
| Dec 31, 2024 | 172 | -13 | -7.03% |
| Dec 31, 2023 | 185 | -7 | -3.65% |
| Dec 31, 2022 | 192 | -4 | -2.04% |
| Dec 31, 2021 | 196 | -71 | -26.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Arvinas | 246 |
| Allogene Therapeutics | 152 |
| MapLight Therapeutics | 133 |
| Neurogene | 131 |
| Aclaris Therapeutics | 73 |
| Oculis Holding AG | 60 |
| Altimmune | 57 |
PBYI News
- 3 days ago - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Puma Biotechnology starts Phase 2 study of alisertib in small cell lung cancer - TheFly
- 21 days ago - Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer - Business Wire
- 24 days ago - Puma Biotechnology Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference - Business Wire
- 5 weeks ago - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Puma Biotechnology price target raised to $6 from $5 at TD Cowen - TheFly
- 2 months ago - Puma Biotechnology reports Q2 EPS 19c vs 15c last year - TheFly